Literature DB >> 23933367

Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate, vaccines, Jeju, Republic of Korea, 5-7 September 2012.

Chris Jones1, Chung Keel Lee, Chiyoung Ahn, Jinho Shin, Ivana Knezevic.   

Abstract

Typhoid fever is a gastrointestinal disease transmitted through the ingestion of contaminated water or food. The bacterium, Salmonella enterica subspecies enterica serovar Typhi is an important cause of illness and death in many poor countries where access to safe water and basic sanitation is limited. Humans are the only natural host and reservoir of S. Typhi. Typhoid fever causes around 21 million cases and at least 200,000 deaths per year. Currently, several groups are developing typhoid conjugate vaccines that are expected to be safe and effective in infancy or early childhood. The World Health Organization convened a meeting, in collaboration with the Korea Food and Drug Administration, with experts group in September 2012 to develop guidelines for regulatory evaluation of the quality, safety and efficacy of typhoid conjugate vaccines. This report summarizes collective views on scientific and technical issues that need to be considered in the guidelines.
Copyright © 2013. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Conjugate vaccine; Regulatory evaluation; Typhoid fever; World Health Organization

Mesh:

Substances:

Year:  2013        PMID: 23933367     DOI: 10.1016/j.vaccine.2013.07.070

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.

Authors:  Shousun C Szu; Keith P Klugman; Steven Hunt
Journal:  Vaccine       Date:  2014-03-13       Impact factor: 3.641

2.  Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies.

Authors:  Peter Rigsby; Emma Beamish; Jason Hockley; Eleanor Atkinson; Krisztina Hitri; Elizabeth Jones; Jae Seung Yang; Firdausi Qadri; Novilia S Bachtiar; Sean C Elias; Akshay Goel; Ravipratapnarayan Mishra; Raju Dugyala; Marcela F Pasetti; James E Meiring; Maurice Mbewe; Melita A Gordon; Andrew J Pollard; Alastair Logan; Sjoerd Rijpkema
Journal:  Biologicals       Date:  2020-06-20       Impact factor: 1.856

Review 3.  Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic Design.

Authors:  Yi-An Yang; Alexander Chong; Jeongmin Song
Journal:  Vaccines (Basel)       Date:  2018-07-24

4.  Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.

Authors:  Sjoerd Rijpkema; Jason Hockley; Alastair Logan; Peter Rigsby; Eleanor Atkinson; Celina Jin; David Goldblatt; Haoyu Liang; Novilia S Bachtiar; Jae Seung Yang; Akshay Goel; Venkatesan Ramasamy; Marcela F Pasetti; Andrew J Pollard
Journal:  Biologicals       Date:  2018-09-07       Impact factor: 1.856

5.  Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT).

Authors:  Eun Young Lee; Ju Yeon Park; Deok Ryun Kim; Manki Song; Sushant Sahastrabuddhe; Hun Kim; Yun Chon; Jae Seung Yang
Journal:  PLoS Negl Trop Dis       Date:  2020-03-23

6.  The Outer Membrane Vesicles of Salmonella enterica Serovar Typhimurium Activate Chicken Immune Cells through Lipopolysaccharides and Membrane Proteins.

Authors:  Hongxiao Cui; Yajun Sun; Hua Lin; Yan Zhao; Xin Zhao
Journal:  Pathogens       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.